Yes, I believe that is the most likely outcome. Humanized monoclonal antibodies are the future of HIV treatment. If Gilead wants to keep the title of HIV treatment king, along with their market share, then they will need to be leading the pack into this next era of treatment. And you can apply that same concept to any Gilead competitor that wants to try to take a piece of the pie.
It is also possible that they partner but I would only expect that if CytoDyn had a serious ace in the hole, like a different treatment (probably not including GvHD) that they dont want to share. Something very promising. Or if they got an incredible partnership offer.
But, yes an acquisition is most likely imo.
News 
Market Data 
Discover 
AI
